Evidence map›Paper›PMID 16262208›Full record

ReviewDialogues in clinical neuroscience2005

The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia.

David L Braff, Gregory A Light

Registry-linked trialAbstract readReview
In one paragraph

Review in Dialogues in clinical neuroscience, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02832401 (The Impact of Caffeine on Cognition in Schizophrenia), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02832401 nacompletednot on this mapstarted 2016, after this paper: background citation

The Impact of Caffeine on Cognition in Schizophrenia

TypeinterventionalSponsorNova Scotia Health AuthorityRan2016 to 2019Enrolled24ConditionsSchizophrenia, CaffeineArmsCaffeine, Placebo
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Sex as a Biological Variable: Who, What, When, Why, and How.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David L BraffDepartment of Psychiatry, University of California, San Diego, 9500 Gilman Drive, Mail Code 0804, La Jolla 92093, USA. dbraff@ucsd.edu
Gregory A Light

Funding

The Genetics of Endophenotypes and SchizophreniaR01MH065571 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 2003 to 2013
$7.0M
SENSORY GATING &HABITUATION IN SCHIZOPHRENIAR01MH042228 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 1987 to 2015
$6.5M
SENSORY GATING AND HABITUATION IN SCHIZOPHRENIAR37MH042228 · NIMH · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BRAFF, DAVID L. · 1993 to 2002
$1.3M
NIMH NIH HHS MH042228NIMH NIH HHS MH065571
6 · The paper itself

Abstract

Specifying the complex genetic architecture of the "fuzzy" clinical phenotype of schizophrenia is an imposing problem. Utilizing metabolic, neurocognitive, and neurophysiological "intermediate" endophenotypic measures offers significant advantages from a statistical genetics standpoint. Endophenotypic measures are amenable to quantitative genetic analyses, conferring upon them a major methodological advantage compared with largely qualitative diagnoses using the Diagnostic and Statistical Manual of Mental Health, 4th Edition (DSM-IV). Endophenotypic deficits occur across the schizophrenia spectrum in schizophrenia patients, schizotypal patients, and clinically unaffected relatives of schizophrenia patients. Neurophysiological measures, such as P50 event-related suppression and the prepulse inhibition (PPI) of the startle response, are endophenotypes that can be conceptualized as being impaired because of a single genetic abnormality in the functional cascade of DNA to RNA to protein. The "endophenotype approach" is also being used to understand other medical disorders, such as colon cancer, hemochromatosis, and hypertension, where there is interplay between genetically conferred vulnerability and nongenetic stressors. The power and utility of utilizing endophenotypes to understand the genetics of schizophrenia is discussed in detail in this article.

Indexed as

PhenotypeAnimalsBrainEvoked Potentials, AuditoryHumansSchizophrenia

Identifiers

PMID16262208
PMCPMC3181726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.